TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04088045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma and 5% dextrose solution injections.
Description: One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves.
Study: NCT01518907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Subdermal dose
Study: NCT03316807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study: NCT04569019

Intervention type: OTHER
Intervention: Vacciantion status in health care workers
Description: Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
Study: NCT00760344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
Study: NCT04380077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy with sulfur hexafluoride gas
Description: vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with balanced salt solution
Description: vitreous substitution with balances salt solution during vitrectomy
Study: NCT01708434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT03329300

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family-based Behavioral Treatment (FBT)
Description: Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
Study: NCT04218747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA 365 Demonstration Benefits
Description: Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
Study: NCT02926911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery +/- radiation choice for endocrine therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Monitoring
Description: Choice for endocrine therapy
Study: NCT03482362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
Study: NCT02669615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan HCl for injection (propylene glycol free)
Description: During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
Study: NCT02430753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT01181791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present.
Study: NCT01895036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study: NCT03956693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEADS: UP
Description: HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories.
Study: NCT02168322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen membrane
Description: bovine collagen membrane used for selective tissue regeneration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen membrane
Description: collagen bovine occlusive membrane for selective tissue regneration
Study: NCT02165995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Mapping
Description: Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech Mapping
Description: Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
Study: NCT03004404

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)
Study: NCT04482738

Intervention type: OTHER
Intervention: High-calorie meal
Description: Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.

Intervention type: OTHER
Intervention: High-calorie meal
Description: Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
Study: NCT03703674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Granulocyte-colony stimulating factors (G-CSF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCSF
Description: Granulocyte-colony stimulating factors (G-CSF)
Study: NCT01383252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water infusion in lieu of air insufflation
Description: Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air method
Description: Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
Study: NCT02652559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous measurements of PCO2
Description: PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous measurements of PCO2
Description: PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG
Description: Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG
Description: Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home initiation of NIV
Description: The primary aim of the study is to compare home and inhospital initiation of NIV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhospital initiation of NIV
Description: The primary aim of the study is to compare home and inhospital initiation of NIV
Study: NCT00482482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation
Description: on weekly basis for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: on weekly basis for 8 weeks
Study: NCT03894761

Intervention type: OTHER
Group type: OTHER
Intervention: Night Pain in Patients with Rotator Cuff Syndrome
Description: The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
Study: NCT04474054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation to treat paroxysmal atrial fibrillation
Description: A pulmonary vein isolation will be performed using catheter ablation
Study: NCT03004404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: powder for reconstitution of an oral solution (PfoS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: BI 730357 film-coated tablet
Study: NCT02103114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thrombin III
Description: Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4~* expressed as a % normal level based on functional ATIII assay

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo
Study: NCT02046512

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
Study: NCT02509078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besylate
Description: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
Study: NCT00675077

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT06178718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: The drug will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: The drug will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: The drug will be administered once in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: The drug will be administered once in each group.
Study: NCT02046512

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT03883464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Restriction in postoperative fat diet
Study: NCT01617122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage OX174
Description: Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
Study: NCT04636762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic Radiation Dose: 3Gy, QD, total dose: 30-45Gy; Particpants with brain metastases：metastatic lesions≤3:whole brain radiotherapy with local simultaneous PGTV:50Gy/10F；metastatic lesions\>3:whole brain radiotherapy PTV:30Gy/10F.
Study: NCT02016378

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bias retraining
Description: Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham retraining
Description: Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
Study: NCT03157245

Intervention type: DIAGNOSTIC_TEST
Intervention: DOPPLER ULTRASOUND
Description: MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
Study: NCT05210075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful with your Baby program
Description: The training Mindful with your baby consists of eight weekly 2-h sessions, plus a follow-up session 8 weeks later. The first and the fifth sessions are with the mothers only. The rest of the sessions are with both mothers and babies present. The sessions are finished by explaining the new home practices. Home practice consists of reading handouts about mindfulness and mindful parenting for mothers with a baby, formal and informal meditation practice.
Study: NCT03758495

Intervention type: OTHER
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.

Intervention type: OTHER
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.

Intervention type: OTHER
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
Study: NCT00478205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept (donepezil SR 23 mg)
Description: Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept (donepezil IR 10 mg)
Description: Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.
Study: NCT01132469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection
Description: 5-years follow-up after Endoscopic Submucosal Dissection
Study: NCT02850042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupation-based practice (OBP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified-constraint induced therapy (m-CIT)
Study: NCT03214445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sealing margins with flow composite
Description: Seal the margin of restoration with Composite flow with nanofiller

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sealing margins with seal
Description: Seal the margin of restoration with sealant without filler
Study: NCT00696488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil 0.5%
Description: Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
Study: NCT03451708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKS
Description: Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKS
Description: Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKS
Description: Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKS
Description: Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
Study: NCT04467047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells infusion
Description: Intravenous 1\*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion